Category: MassDevice Q&A
Rahul Aras, the CEO of SironRX Therapeutics and Juventas Therapeutics, on the challenges of his dual role and his companies' stem-cell-based technology.
Many business professionals likely dream of the day when they’ll run a company as chief executive, but how many hope to lead two start-ups simultaneously?
We're on the cusp of a significant new era in medical device design, Nano Surfaces CEO Joe Gatto tells MassDevice, in which their very surfaces will build themselves and be able to operate at the molecular level.
Coming generations of implanted medical devices will interact with the human body at the molecular level, using sophisticated nano-coatings to not only thwart microbial growth but to perform biological operations.
That's the prediction of Nano Surfaces founder, president and CEO Joe Gatto. The Boston-based firm is developing technology it's licensed from Cornell University to create self-assembling, anti-microbial coatings on a nanotech scale — and Gatto says that's just the beginning. To prove it, he's hitting to road to raise a Series A round from institutional investors.
Nfocus CEO Eric Milledge tells MassDevice that the Palo Alto company is focused on the long term, intent on changing the way brain aneurysms are treated.
NFocus Neuromedical Inc. is developing a new treatment for brain aneurysms that could end up giving companies like Johnson & Johnson (NYSE:JNJ), Stryker (NYSE:SYK) and Covidien (NYSE:COV) a real headache.
Semprus BioSciences Corp. hopes to reduce the 60,000 deaths and $11 billion in costs related to "surface failures" of vascular catheters with its Sustain technology for coating medical devices.
Medical device developers have long sought to reduce the risks involved with implants by applying coatings to prevent both bacteria and blood from sticking to the objects once they're inside the body.
But coatings can wear off or otherwise lose their effectiveness. Semprus BioSciences Inc. is developing a solution to this fundamental limitation of implanted medical devices with its Sustain technology, which CEO David Lucchino describes as a "physical extension" of the device's material.
The use of data, algorithms and social networks has changed the way we consume pop culture. Can it also change the way we innovate?
There's a lot of loot sitting on the med-tech sidelines these days. According to research by MassDevice.com, the top five medical device companies are sitting on a combined $17 billion in free cash.
With all that money to burn, you'd think that the med-tech mergers & acquisitions market would be a busy place. But aside from a few blockbuster deals and some lower-value transactions, medical device M&A activity is in a slump.
But there are also a slew of med-tech start-ups slavering for a taste of all that cash, hoping to land a corporate sponsor who will shepherd them through the development phase and buy the technology outright once it (presumably) proves out.
After a stellar 2010, Michael Mussallem, CEO of Edwards Lifesciences Corp., is feeling bullish on transcatheter heart valves and the future of the Irvine, Calif.-based cardiac device maker.
You could forgive Michael Mussallem if he didn't want to bid farewell to 2010.
While the rest of us were still trying to pull our heads out of the lingering effects of the so-called "Great Recession," the 57-year-old chief executive of Edwards LifeSciences Corp. (NYSE:EW) was busy watching his company clean up on Wall Street and set itself up for a sweet run this year.
Retina Implant AG's sub-retinal implant — a microchip inserted into the eye to restore vision — is currently undergoing a second clinical trial with commercialization in Europe as close as a year off.
Restoring vision to the blind is the sort of feat reserved for ancient religious texts and modern science fiction novels. But a company in Germany did just that with an eye implant.
Retina Implant AG is in the process of developing a sub-Retina Implant, designed to be inserted into the eye to treat back-of-the-eye disorders. A first clinical trial showed that the device can enable people suffering from a certain type of macular degeneration to see. The patients had retinitus pigmentosa, an inherited and incurable degenerative condition that causes tunnel vision and often, eventually, complete blindness. Retina Implant estimates that the condition affects about 200,000 people in the U.S. and Europe.